EdgarLookup

60 DEGREES PHARMACEUTICALS, INC. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that 60 DEGREES PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $437.6K Nov 13, 2025
Q2 2025 Jun 30, 2025 $100.9K Aug 13, 2025
Q1 2025 Mar 31, 2025 $163.6K May 15, 2025
Q3 2025 Sep 30, 2024 $135.3K Nov 13, 2025
Q2 2025 Jun 30, 2024 $125.0K Aug 13, 2025
Q1 2025 Mar 31, 2024 $105.7K May 15, 2025
Q3 2024 Sep 30, 2023 $51.2K Nov 14, 2024
Q2 2024 Jun 30, 2023 $59.5K Aug 14, 2024
Q1 2024 Mar 31, 2023 $17.2K May 15, 2024
Q3 2023 Sep 30, 2022 $168.2K Nov 20, 2023
Q2 2023 Jun 30, 2022 $45.2K Aug 25, 2023

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($2.32M) Nov 13, 2025
Q2 2025 Jun 30, 2025 ($1.73M) Aug 13, 2025
Q1 2025 Mar 31, 2025 ($1.88M) May 15, 2025
Q3 2025 Sep 30, 2024 ($2.16M) Nov 13, 2025
Q2 2025 Jun 30, 2024 ($4.17M) Aug 13, 2025
Q1 2025 Mar 31, 2024 $430.5K May 15, 2025
Q3 2024 Sep 30, 2023 $4.18M Nov 14, 2024
Q2 2024 Jun 30, 2023 ($3.34M) Aug 14, 2024
Q1 2024 Mar 31, 2023 ($2.60M) May 15, 2024
Q3 2023 Sep 30, 2022 ($1.45M) Nov 20, 2023
Q2 2023 Jun 30, 2022 ($2.15M) Aug 25, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($2.33M) Nov 13, 2025
Q2 2025 Jun 30, 2025 ($1.60M) Aug 13, 2025
Q1 2025 Mar 31, 2025 ($1.91M) May 15, 2025
Q3 2025 Sep 30, 2024 ($2.12M) Nov 13, 2025
Q2 2025 Jun 30, 2024 ($4.19M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($1.34M) May 15, 2025
Q3 2024 Sep 30, 2023 ($1.52M) Nov 14, 2024
Q2 2024 Jun 30, 2023 ($788.0K) Aug 14, 2024
Q1 2024 Mar 31, 2023 ($950.7K) May 15, 2024
Q3 2023 Sep 30, 2022 ($215.1K) Nov 20, 2023
Q2 2023 Jun 30, 2022 ($686.9K) Aug 25, 2023